There are currently 113 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
NCT04807530
Recruiting
This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how modulation of mPFC activity impacts the larger self-agency network to mediate changes in self-agency judgments. Our overall hypothesis is that increas... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2024
Locations: UCSF, San Francisco, California
Conditions: Schizophrenia
Register for Updates
Effectiveness of Motivation Skills Training (MST)
NCT05805397
Recruiting
This study will take place at four outpatient clinics serving adults with serious mental illness. Informed consent will be obtained from N=80 individuals with a Diagnostic and Statistical Manual of Mental Illnesses (DSM)-5 diagnosis of schizophrenia or schizoaffective disorder meeting inclusion/exclusion criteria to participate in a randomized controlled trial comparing Motivation Skills Training (MST) to a Healthy Behaviors Control (HBC) group. Eligible participants will receive a baseline asse... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2024
Locations: The Bridge, Inc., New York, New York +1 locations
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04857983
Recruiting
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability. We hypothesize that medications that specifically target sensory information processing deficits, rather than psychotic symptoms per se, will significantly enhance the benefits of a sensory-based targeted cognitive training (TCT) intervention in patients with schizophrenia. We will com... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: Clinical Teaching Facility (CTF B-403 at UCSD Medical Center), San Diego, California
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04414930
Recruiting
These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, including schizophrenia, but do not significantly alter their course or real-life impact. Specific cognitive therapies achieve modest symptom reduction and improved function and cognition in psychosis pat... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/02/2024
Locations: Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
NCT05380583
Recruiting
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth (video conferencing).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/02/2024
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Psychosis, Substance Use, Substance Use Disorders, Family, Cannabis, Marijuana, Alcohol, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Mental Disorder
Register for Updates
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
NCT06174116
Recruiting
The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for 12 weeks, in addition to their regularly prescribed clozapine. During their participation, patients will answer questions about their psychiatric and daily functioning, have... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: UMass Chan Medical School, Worcester, Massachusetts
Conditions: Schizophrenia, Schizo Affective Disorder
Register for Updates
Anti-Inflammatory Challenge in Schizophrenia
NCT05823532
Recruiting
This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per group) to patients with high inflammation. This study is important because schizophrenia can be a chronic and debilitating neuropsychiatric disorder and negative symptoms are some... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/26/2024
Locations: Grady Memorial Hospital, Atlanta, Georgia +1 locations
Conditions: Schizophrenia
Register for Updates
Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia
NCT06389266
Recruiting
The goal of this clinical trial is to compare two active types of transcranial magnetic stimulation in two nicotine-using populations: nicotine-using people with psychosis and nicotine-using people without a diagnosis of a psychotic disorder. The main questions it aims to answer are: Can rTMS change functional connectivity in brain circuits associated with nicotine use? Are those rTMS-induced changes in functional connectivity related to craving? Participants will complete tasks assessing thei... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Schizophrenia, Nicotine Dependence
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/23/2024
Locations: Alkermes Investigator Site, Dothan, Alabama +43 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia
NCT05724810
Recruiting
Purpose of the study: Evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rTMS; hereafter abbreviated as "dTMS") on synaptic density measured with positron emission tomography (PET) and the radiotracer [11C]UCB-J. The investigators also seek to link plasticity changes in the regions targeted by the electric field (especially, the insula) to changes in the functioning of insula circuits and behavioral cigarette usage in patients with schizophrenia (SCZ). Importance of... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/23/2024
Locations: Stony Brook University, Stony Brook, New York
Conditions: Schizophrenia, Smoking Cessation, Tobacco Use
Register for Updates
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
Recruiting
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with ora... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
04/19/2024
Locations: Teva Investigational Site 15739, Los Alamitos, California +5 locations
Conditions: Schizophrenia
Register for Updates